You are using an outdated browser. Please upgrade your browser to improve your experience.

methimazole embryofetopathy

Disease Summary
Associated Targets (0)

Explore Associated Targets
Mondo Description Methimazole embryopathy is a teratogenic embryofetopathy that results from maternal exposition to methimazole (MMI; or the parent compound carbimazole) in the first trimester of pregnancy. MMI is an antithyroid thionamide drug used for the treatment of Graves' disease. In the infant, MMI may result in choanal atresia, esophageal atresia, omphalocele, omphalomesenteric duct anomalies, congenital heart disease (such as ventricular septal defect), renal system malformations and aplasia cutis. Additional features that may be observed include facial dysmorphism (short upslanting palpebral fissures, a broad nasal bridge with a small nose and a broad forehead) and athelia/hypothelia.
Mondo Term and Equivalent IDs
MONDO:0016017:  methimazole embryofetopathy
GARD:0003573: 
Orphanet:1923: 
SCTID:724144006: 
UMLS:C4510379: 
GWAS Targets (0)
No GWAS traits found
Target Novelty (Tin-x)
No novelty measurements found